Navigation Links
MFM researcher earns $3.7M NIH grant to study preterm birth
Date:10/6/2010

Fetal growth is used as a marker of health and well-being in unborn babies as well as children. But, the tools that are currently available to differentiate between a small, healthy fetus and a fetus that is small due to pathologic causes have significant limitations. What if they were improved? Would it save the health care system resources spent monitoring women who might need medical intervention because their fetuses might just be small and healthy? Would it help some women avoid the anxiety such intervention brings?

Those are the questions being addressed by Edward Chien, MD, a physician in the Division of Maternal-Fetal Medicine at Women & Infants Hospital of Rhode Island and an assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University. Dr. Chien recently joined the "The National Standard for Normal Fetal Growth" study designed to develop more accurate algorithms for tracking fetal development and predicting which fetuses are abnormally small and unhealthy. He will serve as the primary investigator on this $3.7-million, two-year grant from the National Institutes of Health (NIH).

Beginning in the next few months, his team will recruit up to 700 pregnant women with low risk for prenatal complications, as well as women pregnant with twins. Because the study will evaluate growth patterns by race and ethnicity, they will recruit specific numbers of Caucasian, Asian, African American and Hispanic women. They will also recruit a specific number of obese women to study the effect of maternal obesity on fetal health and growth.

About 10% of babies born in this country are small. Like children or adults, not all of these babies are unhealthy. This study seeks to identify those individuals who are small and healthy from those who are unhealthy.

"Growth is a longitudinal measure. We hope to develop an algorithm that will look at fetal size, fetal growth and changes in the body during pregnancy, offering a standard for fetal anthropometric parameters throughout gestation," Dr. Chien explained. "This project will evaluate growth trajectories which will help to identify pathologic versus normal growth patterns in both singletons and twins."

To develop the algorithm, the researchers will use standard two-dimensional ultrasounds as well as more sophisticated three-dimensional ultrasounds during pregnancy and compare the predictions against newborn weight to see if there are characteristics visible on the ultrasounds that could be used to more accurately predict the baby's size. Current algorithms for determining newborn size can be off by up to 15%, or as much as one to two pounds.

"We know that growth restricted (small and unhealthy) babies have more complications, such as learning and physical disabilities, and they are more likely to die in utero and after birth. But it is important for us to be able to identify those babies who are smaller but healthy so we can utilize resources for monitoring complicated pregnancies. We expend a significant amount of resources on small but healthy fetuses," Dr. Chien added.

The study will also seek to discern why some babies have growth problems and others do not. Researchers will look at maternal body mass index (BMI), prenatal weight gain and nutritional habits as indicators.

At Women & Infants, investigators include Dr. Chien, and Drs. Hal Pinar and Dwight Rouse. The hospital will also collaborate with Sabrina Craigo, MD, at Tufts Medical Center for recruitment.


'/>"/>

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital
Source:Eurekalert

Related medicine news :

1. Blood test could diagnose Alzheimers disease, UT Southwestern researchers find
2. Better cholesterol drugs may follow Saint Louis University researchers breakthrough
3. Mayo researchers find biomarkers for personalizing radiation cancer treatment
4. Insurance, Race and Poverty Affect Cancer Care, Researchers Report
5. Johns Hopkins researchers turn off severe food allergies in mice
6. UTHealth researchers awarded $15 million for teen pregnancy prevention
7. Researchers discover genetic changes that make some forms of brain cancer more aggressive
8. Researchers find no difference in drugs for macular degeneration
9. Researchers advance biosynthesis of potent anti-cancer drug Taxol
10. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
11. Researchers at the University of Granada associate trigger points with shoulder injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: